Y Intercept Hong Kong Ltd Acquires New Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Y Intercept Hong Kong Ltd purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 15,118 shares of the company's stock, valued at approximately $837,000.

A number of other institutional investors also recently modified their holdings of the company. R Squared Ltd acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth $53,000. Baader Bank Aktiengesellschaft bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $249,000. FMR LLC increased its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after purchasing an additional 3,537 shares during the period. Bleakley Financial Group LLC bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $323,000. Finally, Nations Financial Group Inc. IA ADV acquired a new stake in Tarsus Pharmaceuticals during the fourth quarter worth about $332,000. Institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Price Performance

NASDAQ TARS traded down $1.75 on Monday, hitting $42.73. 511,336 shares of the company were exchanged, compared to its average volume of 643,611. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28. The firm has a 50 day moving average of $50.97 and a two-hundred day moving average of $43.36. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.64 billion, a P/E ratio of -11.21 and a beta of 1.01.

Remove Ads

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. On average, equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. HC Wainwright restated a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Oppenheimer upped their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Guggenheim restated a "buy" rating and set a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. The Goldman Sachs Group upped their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a research note on Friday, November 15th. Finally, Barclays cut their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $61.33.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.